Actively Recruiting
Safety Study of Inhaled Ciclesonide Alvesco to Prevent Lung Disease in Preterm Infants Born Before 30 Weeks
Led by Venkatesh Sampath · Updated on 2026-03-27
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating inhaled ciclesonide CIC as a potential treatment for preterm infants born before 30 weeks gestation who are at high risk of developing bronchopulmonary dysplasia BPD, a serious lung condition. The study aims to assess the safety and systemic absorption of CIC, a synthetic glucocorticoid, while measuring its biological activity in blood cells. This research addresses the need for effective glucocorticoid therapies that prevent BPD without causing harmful side effects seen with other steroids like dexamethasone.
CONDITIONS
Brief Title
Inhaled Ciclesonide Study in Preterm Infants
Research Team
V
Venkatesh Sampath, MD
M
Miah R Ruffin, BA, CCRC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
